Renal outcomes after contrast exposure in patients with diabetes who use sodium-glucose cotransporter 2 inhibitors.
Chih-Wei ChenFu-You SuPing-Ping WangMing-Tsang ChuangYi-Cheng LinChih-Chin KaoChun-Yao HuangPublished in: Postgraduate medical journal (2023)
SGLT2i may be safely used in diabetic patients needing contrast exposure. The risk of a MAKE may be lower in SGLT2i users than in nonusers.